Protalix tumbles 30% on FDA rejection of Gaucher's disease drug
This article was originally published in Scrip
Executive Summary
Protalix BioTherapeutics may have missed its opportunity to make a dent in the sales of Genzyme's Cerezyme (imiglucerase for injection)